Prognostic Models for HCC Based on Tumor Micronecrosis
Development and Validation of Novel Models Including Tumor Micronecrosis for Predicting the Postoperative Survival of Patients With Hepatocellular Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tingbo Liang, PhD
- Email: liangtingbo@zju.edu.cn
Study Contact Backup
- Name: Qi Zhang, MD
- Phone Number: 13819137113
- Email: qi.zhang@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital, School of Medicine, ZheJiang University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- pathologically diagnosed as HCC;
- curative hepatectomy with R0 resection;
- conserved liver function with Child Pugh class A or B
Exclusion Criteria:
- with macrovascular invasion or extrahepatic metastasis;
- receiving other anti-tumor treatments such as TACE or systemic drugs;
- with other primary cancers;
- incomplete follow-up data;
- without sufficient formalin-fixed, paraffin-embedded (FFPE) specimens for micronecrosis evaluation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
training cohort
HCC patients receiving curative hepatic resection
|
whether HCC patients having tumor micronecrosis or not
|
|
validation cohort
HCC patients receiving curative hepatic resection
|
whether HCC patients having tumor micronecrosis or not
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the Harrell concordance index (C-index)
Time Frame: Up to 5 years
|
Up to 5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the time-dependent area under the receiver operating characteristic curve(tdAUROC)
Time Frame: Up to 5 years
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PMforHCC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.